COLLCollegium Pharmaceutical, Inc.
Price
-31%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: the market
Quality mixed, nothing alarming, undemanding price, growing in the filings, the market against it.
Jornay PM is a central nervous system (“CNS”) stimulant prescription medicine that contains methylphenidate HCl, a Schedule II methylphenidate, which was approved by the U.S. Food and Drug Administration (“FDA”) in August 2018 for the treatment of ADHD in people six years of age and older and currently the only FDA-approved stimulant medication that is dosed in the evening.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Collegium Pharmaceutical, Inc. (COLL) reported revenue of $200M in Q2 2026 (quarter ended Jun 30, 2026), up 6.3% from the same quarter a year earlier. That came with a gross margin of 55% and net loss of $15M. For the full year FY2025, revenue was $781M (+24% year on year) and net income $63M. Its largest product in Q2 2026 was Belbuca at $58M, 29% of the disclosed total, just ahead of Jornay Pm at 23%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 19, 2026As previously disclosed, Collegium Pharmaceutical, Inc. (the “Company”) is party to a License Agreement (U.S.), dated as of January 13, 2015, with Grünenthal GmbH (“Grünenthal”) (as amended, the “Grünenthal License”) which the Company assumed pursuant to a Consent Agreement, dated as of January 30, 2020 between the …Material agreement terminated · Form 8-K
- Aug 13, 2026On August 12, 2026, Collegium Pharmaceutical, Inc. (“Collegium” or the “Company”) announced the execution of an accelerated share repurchase agreement (the “ASR Agreement”) with Jefferies LLC to repurchase $50 million of the Company’s common stock.Other event · Form 8-K
- May 12, 2026As previously disclosed, on March 19, 2026, Collegium Pharmaceutical, Inc. (the “Company”), entered into an Equity Purchase Agreement (the “Purchase Agreement”) with Corium Therapeutics Holdings, LLC, a Delaware limited liability company (“Commave Seller”), and Corium, LLC, a Delaware limited liability company …Acquisition or disposition completed · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $199.9MThe company’s own SEC segment disclosure.
- Belbuca$57.7M29%
- Jornay Pm$46.1M23%
- Xtampza ER$45.0M23%
- Nucynta ER$15.7M8%
- Nucynta IR$14.4M7%
- Azstarys$12.9M6%
- Other (3)$8.2M4%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #8 of 39 by RyuScore